CSPC Pharmaceutical Group (HKG:1093) received approval from China's National Medical Products Administration to conduct clinical trials of JMT108 in China.
The indication for this approval is advanced malignant tumors, according to a Wednesday filing with the Hong Kong bourse.
Preclinical studies have demonstrated that the product has a broad variety of indications with significant anti-tumor effects and a good safety profile.
Shares of the drugmaker were up nearly 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.